The War on Alzheimer’s: Progress and Challenges of Biopharmaceutical Research

Alzheimer’s disease steals memories, relationships and independence. It is a ruthless, devastating disease ravaging more than 5 million people in the United States alone, and is the sixth-leading...
Read More
New PhRMA and Epilepsy Foundation Report: 420 Medicines in Development for Neurological Disorders

It’s hard to imagine, but there are currently more than 50 million Americans – nearly one-sixth of our population – affected by some type of neurological disorder. While some of these are more...
Read More
Week in Review: The Latest from PhRMA

Healthy Outlook: The Cancer Support Community’s Rob Goldsmith highlighted a new report from his organization that found discrepancies in the definition of value in cancer care. July 15 Webcast Will...
Read More
Alzheimer’s disease has a devastating impact on patients, their loved ones and the caregivers who help them navigate their daily lives. It’s a particularly cruel disease – one that is especially...
Read More
New Video: How Medicines Can Curb Health Care Costs

Hospital visits, surgeries and long-term care place a heavy burden on our nation’s health care system, and the weight is only projected to increase. In just the next decade, the U.S. will spend $13.5...
Read More
Week in Review: Commitment to Patient Well-Being

For the biopharmaceutical industry, patient well-being is at the center of everything we do. In keeping patients at the forefront, we are doing all that we can to help people live longer, healthier...
Read More
Strong R&D Investment the Best Bet to Slow Alzheimer’s Growing Threat

Since the publication of this post, the Alzheimer’s Association released a new report, “Changing the Trajectory of Alzheimer's Disease: How a Treatment by 2025 Saves Lives and Dollars,” that examines...
Read More
Wanted: A Balanced Discussion on Health Care Costs

1-26-15 UPDATE: In response to the op-ed referenced below, The New York Times posted a Letter To The Editor from PhRMA President & CEO John Castellani.
Read More
Collaboration Between PhRMA and Scientific American Highlights Biomedical Science

Scientific progress is complex, time-consuming and expensive. Researchers continue to broaden our collective understanding of disease with the hope that new findings will lead to advancements that...
Read More
Never Too Late to Plan for Retirement

At the breakfast table yesterday, I was reading the New York Times which included a special supplement on retirement. It was full of the kinds of articles that can make a middle aged person panicky...
Read More